We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
-10.45%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$135M
AUM Growth
-$151M
(-53%)
Cap. Flow
-$109M
Cap. Flow
% of AUM
-80.48%
Top 10 Holdings %
Top 10 Hldgs %
67.63%
Holding
31
New
1
Increased
3
Reduced
16
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
+$4.96M |
| 2 |
Guardant Health
GH
|
+$3.76M |
| 3 |
Rapid Micro Biosystems
RPID
|
+$1.93M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$1.48M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Natera
NTRA
|
+$25M |
| 2 |
Repligen
RGEN
|
+$18.5M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$12.5M |
| 4 |
Sarepta Therapeutics
SRPT
|
+$10.8M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$10.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Natera
NTRA
$37.5B
| – | – |
-268,000
| Closed | -$25M |
|
|
27
Repligen
RGEN
$7.44B
| – | – |
-70,000
| Closed | -$18.5M |
|
|
28
Sarepta Therapeutics
SRPT
$1.66B
| – | – |
-120,000
| Closed | -$10.8M |
|
|
CYT
29
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
| – | – |
-319,538
| Closed | -$3.63M |
|
|
NSTG
30
DELISTED
NanoString Technologies, Inc.
NSTG
| – | – |
-185,000
| Closed | -$7.81M |
|
|
MRTX
31
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-85,000
| Closed | -$12.5M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q1 2022 Portfolio in Review
As of Q1 2022, Ally Bridge Group held 31 positions worth $135M, down 53% from $286M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Ally Bridge Group withdrew a net $109M in Q1 2022, closing 10 positions and reducing 16 holdings. Its most notable exit was Natera, an estimated $25M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.
Against the trend, Ally Bridge Group opened a new position in Cerevel Therapeutics Holdings, Inc. Common Stock worth $5.95M.
- Ally Bridge Group's largest Q1 2022 buy was Cerevel Therapeutics Holdings, Inc. Common Stock: 170,000 shares worth $5.95M.
- Ally Bridge Group added most to Guardant Health in Q1 2022, an estimated $3.76M increase.
- Ally Bridge Group's biggest Q1 2022 reduction was Arvinas, cutting an estimated $5.45M.
- Ally Bridge Group fully exited Natera in Q1 2022, selling an estimated $25M.
- Ally Bridge Group's ten largest holdings make up 68% of its $135M portfolio in Q1 2022.
- Ally Bridge Group opened 1 new position and closed 10 in Q1 2022.
- Ally Bridge Group's portfolio value fell 53% quarter-over-quarter to $135M.
Based on Ally Bridge Group's 13F filing for Q1 2022, filed 16 May 2022.